Understanding Mayo V. Prometheus

Law360, New York (July 10, 2012, 1:29 PM EDT) -- The unanimous U.S. Supreme Court decision in Mayo Collaborative Services Inc. v. Prometheus Laboratories Inc., 566 U.S. __ (2012) (slip op. at 5-6), threatens loss of patent protection for biotechnological and pharmaceutical innovations. The court held that Prometheus’ methods for optimizing drug dosages in treating immune-mediated gastrointestinal (i.e., GI) diseases were invalid under statutory patent law (35 U.S.C. § 101) as drawn to patent-ineligible subject matter.

The convoluted history of the case includes the granting of two petitions for certiorari and primarily concerned the machine-or-transformation (MOT)...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.